文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

I型干扰素激活的NK细胞在体内控制真性红细胞增多症

Type-I interferon-activated NK cells control polycythemia vera in vivo.
PubMed 文献 · Blood · 2026-01-01

本研究在真性红细胞增多症(PV)小鼠模型及接受IFN-α治疗的患者中,发现NK细胞是IFN-α治疗PV的关键免疫效应细胞。IFN-α诱导骨髓CD27+ NK细胞扩增,患者CD56bright NK细胞频率增加且与分子学反应相关;NK细胞清除则消除IFN-α疗效。NK细胞以TNF-α依赖方式优先杀伤Jak2VF突变造血干祖细胞,且直接感知基础I型干扰素对延缓疾病进展至关重要。

要点

  • IFN-α治疗PV依赖NK细胞,清除NK细胞可消除其疗效。
  • IFN-α诱导骨髓CD27+ NK细胞扩增,患者CD56bright NK细胞增加并与分子学反应相关。
  • NK细胞以TNF-α依赖方式优先杀伤Jak2VF突变造血干祖细胞。

核心结论

  • NK细胞是IFN-α治疗PV体内控制疾病所必需的主要免疫效应细胞。
  • NK细胞直接感知基础水平I型干扰素对延缓MPN疾病进展至关重要。

研究设计与样本

  • 采用PV转基因小鼠模型及接受IFN-α治疗的PV或原发性血小板增多症患者。
  • 通过NK细胞清除、I型干扰素受体缺失及体外杀伤实验进行机制研究。

主要发现

  • IFN-α诱导PV小鼠骨髓CD27+ NK细胞扩增。
  • IFN-α治疗患者CD56bright NK细胞频率增加且与分子学反应相关。
  • NK细胞以TNF-α依赖、不依赖IFN-γ或NKG2D的方式优先杀伤Jak2VF突变造血干祖细胞。
  • 清除NK细胞消除IFN-α疗效;NK细胞缺失或NK细胞上I型干扰素受体缺失的PV小鼠在无外源IFN-α时疾病进展加速。

临床怎么用

  • PV患者接受IFN-α治疗时,NK细胞频率(尤其CD56bright)可能作为分子学反应的免疫监测指标。
  • NK细胞激活有望成为改善MPN治疗结局的潜在策略。

局限性

  • 机制主要基于PV转基因小鼠模型,人体直接证据限于IFN-α治疗患者中CD56bright NK细胞频率与分子学反应的相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycythemia vera (PV) is a clonal hematopoietic stem cell disorder resulting in overproduction of erythrocytes. Although interferon alfa (IFN-α) has shown therapeutic efficacy in PV and other myeloproliferative neoplasms (MPN), its precise mechanism of action remains poorly understood. In this study, we identify natural killer (NK) cells as primary immune effectors responsive to IFN-α treatment in PV essential for disease control in vivo. Using a transgenic mouse model of PV, we demonstrate that IFN-α induces the expansion of CD27+ NK cells in the bone marrow. In patients with PV or essential thrombocythemia undergoing IFN-α therapy, the frequency of CD56bright NK cells is increased and correlates with the molecular response. Depletion of NK cells abrogated the therapeutic effects of IFN-α. In vitro experiments demonstrate that NK cells preferentially killed Jak2VF mutant hematopoietic stem and progenitor cells in a tumor necrosis factor-α-dependent manner and independent of IFN-γ or NKG2D. Notably, PV mice depleted of NK cells or lacking type-I interferon receptor on NK cells showed accelerated disease progression in the absence of exogenous IFN-α. This suggests that direct sensing of basal levels of type-I interferons by NK cells is essential for attenuating disease progression, emphasizing a critical role for NK cells in immune surveillance of MPN. These findings offer new insights into type-I interferon-mediated immune modulation in MPN and highlight the potential of NK cell activation to improve therapeutic outcomes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lossa J, Schnöder TM, Ronge Z, et al. Type-I interferon-activated NK cells control polycythemia vera in vivo. Blood. 2026. PMID: 42233405. doi:10.1182/blood.2026033951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。